(20510) A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH
Active, not recruitingCTIS2023-505830-89-00
Bayer Consumer Care AG, Bayer AGmetastatic castrate resistant prostate cancer (mCRPC)
Start: 2020-08-05Target: 514Updated: 2025-10-07